PROGRAM AGENDA

Innovate 2020: Stanford Retina Innovation Summit Session III Sunday, December 6, 2020 10:00 AM – 12:30 PM ET

This activity is jointly provided by Global Education Group and iVista Medical Education, Inc.

This activity is supported by an independent medical education grant from Vision, LLC, EyePoint Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and REGENXBIO Inc.

Target Audience The educational design of this activity addresses the needs of practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons involved in the treatment of patients with retinal disease.

Statement of Need/Program Overview The Stanford Retina Innovation Summit will take place virtually over 3 sessions. The summit series will focus exclusively on the latest, game-changing innovations in medical and surgical retina, imaging, and pharmacotherapy. Topics will include the latest retina pharmacotherapy clinical trials data, updates on artificial intelligence (AI) for diagnosis, advances in molecular surgery for the precision treatment of previously untreatable blinding diseases, and novel drug delivery technologies designed to improve patient care. The program will also focus on the role of imaging in determining new biomarkers for disease. Surgical innovation will be addressed in terms of new instrumentation, visualization enhancements, and image- guided surgery.

This meeting will showcase the journey and insights of leaders in retinal innovation, with the goal of equipping retina specialists to work collaboratively to solve unmet needs for our patients.

Educational Objectives After completing this activity, the participant should be better able to:

• Examine the latest clinical data on emerging pharmacotherapeutics in retina • Evaluate key trials for macular and inherited retinal diseases • Assess innovations across imaging, medical devices, AI, and pharmacotherapeutics • Recognize requirements for successful innovation in the academic and private practice settings

Faculty

Audina Berrocal, MD Tamer Mahmoud, MD, PhD University of Miami Health System Associated Retinal Consultants, PC Miami, FL Royal Oak, MI David S. Boyer, MD Prithvi Mruthyunjaya, MD, MHS (Co-Director) Retina-Vitreous Associates Medical Group Stanford Health Care Beverly Hills, CA Palo Alto, CA Diana V. Do, MD (Co-Director) Quan Dong Nguyen, MD, MSc (Co-Director) Stanford Health Care Stanford Health Care Palo Alto, CA Palo Alto, CA Justis P. Ehlers, MD Mark Pennesi, MD, PhD Cole Eye Institute, Cleveland Clinic OHSU Casey Eye Institute Cleveland, OH Portland, OR Allen C. Ho, MD, FACS Dante J. Pieramici, MD Wills Eye Hospital California Retina Consultants Philadelphia, PA Santa Barbara, CA Arshad Khanani, MD, MA Ruwan A. Silva, MD, MPhil Sierra Eye Associates Stanford Health Care Reno, NV Palo Alto, CA Jennifer Lim, MD Stephen Smith, MD (Co-Director) Lions of Illinois Eye Research Institute Stanford Health Care Chicago, IL Palo Alto, CA Anat Loewenstein, MD Cynthia A. Toth, MD Tel Aviv Medical Center Duke Eye Center Tel Aviv, Israel Durham, NC Vinit B. Mahajan, MD, PhD Charles C. Wykoff, MD, PhD Stanford Health Care Retina Consultants of Houston Palo Alto, CA Houston, TX

*Eugene de Juan, MD; Anne E. Fung, MD; Anirvan Ghosh, PhD; Derek Y. Kunimoto, MD, JD; Baruch D. Kuppermann, MD, PhD; Linda A. Lam, MD, MBA; Robert MacLaren, MD, ChB DPhil, FRCOphth, FRCS FACS., FMedSci; Camille Samuels, MBA; and Nathan Steinle, MD are only involved via a non-CME capacity.

Physician Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and iVista Medical Education, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Global Education Group designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].

Instructions to Receive Credit In order to receive credit for this activity, the participant must attend the webinar, score 70% or better on the posttest, and complete the program evaluation.

Fee Information& Refund/Cancellation Policy There is no fee for this educational activity.

System Requirements Recommended to use Google Chrome or Microsoft Firefox as the browser.

Disclosure of Conflicts of Interest Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship Consultant/Independent Contractor: Alcon Surgical Audina Berrocal, MD Honoraria: Zeiss, AGTC, ProQR, Visunex, Phoenix, , , Aerie Consultant/Independent Contractor: 4DMT,Acuela (C); Adverum (C, R); Aerie Pharmaceuticals (R); Aerpio (C, R); Aldeyra(C); Allegro (C); Allergan (C, R); Alzheon (C,); Apellis (C, R); Bayer (C); Chengdu Kanghong (C, R); Clearside Biomedical (C, R); EyePoint (C); Gemini Therapeutics (R); Galimedex (C,);/Roche (C, R); Graybug Vision (R); Gyroscope (C,);IONIS Pharmaceuticals (R); Hemera (C,); Iveric (C,); jCyte (C,);Kala (C,); KalVista (C,); Kodiak (C, R); Neurotech (R),NGM ©; Novartis (C, R); ONL Therapeutics (C); Ocular Therapeutics (C,); Ocunexus (C,); Opthea (R); Outlook Therapeutics (R); Oxurion (C); Recens Medical (C, R); Regeneron (C, R); Regenxbio (C, R); Roche (C,R); Santen (C, R); Santen (R,);Sciflor (C,R,) Stealth (C,R); Takeda (C) Thea (C,). Advisory Board: 4DMT,Acuela (C); Adverum (C, R); Aerie Pharmaceuticals (R); Aerpio (C, R); Aldeyra(C); Allegro (C); Allergan (C, R); Alzheon (C,); Apellis (C, R); Bayer (C); Chengdu Kanghong (C, R); Clearside Biomedical (C, R); EyePoint (C); Gemini Therapeutics (R); Galimedex (C,);Genentech/Roche (C, R); Graybug Vision (R); Gyroscope (C,);IONIS Pharmaceuticals (R); Hemera (C,); Iveric (C,); jCyte (C,);Kala (C,); KalVista (C,); Kodiak (C, R); Neurotech (R),NGM ©; Novartis (C, R); ONL Therapeutics (C); Ocular Therapeutics (C,); Ocunexus (C,); Opthea (R); Outlook Therapeutics (R); Oxurion (C); Recens Medical (C, R); Regeneron (C, R); Regenxbio (C, R); Roche (C,R); Santen (C, R); Santen (R,);Sciflor (C,R,) David S. Boyer, MD Stealth (C,R); Takeda (C) Thea (C,). Consultant/Independent Contractor: Regeneron, Genentech, Novartis, BI, Kodiak Sciences, Allergan, Asclepix, Graybug Grant/Research Support: Regeneron, BI, Novartis, Arie, Roche Diana V. Do, MD Stock Shareholder: Kodiak Sciences Consultant/Independent Contractor: Novartis; Zeiss; Roche; Regeneron; Genentech; Allegro; Aerpio; Allergan; Alcon; Thrombogenics; Leica Justis P. Ehlers, MD Grant/Research Support: Novartis; Regeneron; Aerpio; Allergan; Alcon; Thrombogenics; Consultant/Independent Contractor: Adverum, Aerie, AGTC, Alcon Laboratories, Inc., Aldeyra, Allegan, Apellis, Asclepix, Beaver-Visitec International, Inc, BioTime, Chengdu Allen C. Ho, MD, FACS Kanghong , Covalent Medical, LLC, Genentech, Graybug, Gyroscope, IRIDEX,

Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, Notal, Ocular Therapeutics, ONL, Optovue, Inc., PanOptica, Regeneron Pharmaceuticals Inc., RegenXBio Grant/Research Support: Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini, Graybug, Gyroscope, Iveric/Ophthotech, Johnson&Johnson, Lineage/BioTime, Lumithera, National Eye Institute, Optovue, Inc., ProQR, Regeneron Pharmaceuticals Inc., RegenXBio, Advisory Board: ONL, Janssen, Allergan, Alcon RegenXBio, Pan Optica, Tyrogenix, BioTime Global Clinical Advisory, Notal Advisory Board, Genentech Ophthalmology Pipeline Advisory Board Consultant/Independent Contractor: Adverum, Allergan, Bausch and Lomb, Chengdu Kanghong, DORC, Eyepoint Pharmaceuticals, Genentech, Gyroscope, Gemini Therapeutics, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, Regenxbio Grant/Research Support: Adverum, Allergan, Chengdu Kanghong, Genentech, Gyroscope, Gemini Therapeutics, Kodiak, Novartis, Iveric Bio, Opthea, Oxurion, Recens Medical, Roche, Regenxbio Arshad Khanani, MD, MA Speaker's Bureau: Genentech, Novartis, Allergan Consultant/Independent Contractor: Genentech, Ophthea, Santen, Quark, Aura Bioscience, Cognition, Alcon, Novartis Grant/Research Support: Genentech, Regeneron, Eyenuk, Stealth, Graybug, Novartis, Chengdu Pharmaceuticals, Allergan, Aldeyra Therapeutics Honoraria: Iveric Bio Advisory Board: Allergan Jennifer Lim, MD Other/Royalty: CRC Press Consultant/Independent Contractor: Allergan, Bayer Health Care, Beyeonics, Forsightlabs, Notal Vision, Novartis, Roche, Syneos Health Anat Loewenstein, MD Stock Shareholder: Beyeonics One Vinit B. Mahajan, MD, PhD Nothing to disclose Tamer Mahmoud, MD, PhD Royalties: For one of the instruments discussed through Vortex Surgical Consultant/Independent Contractor: Aura Biosciences, Castle Biosciences, Arix Biosciences Advisory Board: Castle Biosciences Prithvi Mruthyunjaya, MD, MHS Stock Shareholder: (partner) Consultant/Independent Contractor: Allergan, Asclepix, Bayer, Eluminex, EyePoint, Genentech, Regeneron, Santen Grant/Research Support: Aldeyra, Genentech, Regeneron, Santen Advisory Board: Allergan, Asclepix, Bayer, EyePoint, Genentech, Regeneron, Santen Quan Dong Nguyen, MD, MSc Stock Shareholder: Asclepix Consultant/Independent Contractor: Adverum, AGTC, Allergan/Editas, Astellas Pharmaceuticals, , Blue Rock, IVERIC, Novartis, Ora, RegenexBio, Roche, Viewpoint Therapeutics Grant/Research Support: AGTC, Biogen, Editas, FFB, ProQR, Sanofi Advisory Board: Astena, DTx, Endogena, Eyevensys, Horama, Nayan, Nacuity Pharmaceuticals, Ocugen, Sparing Vision, Verede Other/Royalty (Describe): Data and Safety Monitoring Board: ProQR Therapeutics, Mark Pennesi, MD, PhD Gensight Consultant/Independent Contractor: Genentech, Regeneron, Regenx, Adverum, Gemini Grant/Research Support: Genentech, Regeneron, Apellis, Adverum, Regenx Bio, Greybug, Stealth, Iveric, NGM, Gyroscope, Kodiac, Novartis Dante J. Pieramici, MD Stock Shareholder: Gemini Ruwan A. Silva, MD, Mphil Nothing to disclose Stock Shareholder: iRenix Medical, Inc. Stephen Smith, MD Other/Royalty (Describe): iRenix Medical, Inc. - Co-Founder, employee Consultant/Independent Contractor: EMMES Inc (serve on DSMB for NIH Trial) Cynthia A. Toth, MD Grant/Research Support: NIH and Research to Prevent Blindness

Stock Shareholder: Theia Imaging, LLC Other/Royalty: Alcon royalties for surgical technologies, through my university. Consultant/Independent Contractor: Acucela, Adverum, , Allegro, Allergan, Apellis, Arctic Vision, Bausch and Lomb, Bayer, Chengdu Kanghong (KHB), DORC, EyePoint, Genentech, Gyroscope, IVERIC Bio, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Opthea, Oxurion, Palatin, Polyphotonix, Recens Medical, Regeneron, RegenXBio, Roche, Takeda, Thea Open Innovation Grant/Research Support: Adverum, Aerie Pharmaceuticals, Aldeyra, Apellis, Chengdu Kanghong Biotechnologies (KHB)¬¬¬, Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, IONIS Pharmaceutical, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, Recens Medical, Regeneron, RegenXBio, Roche, Samsung Bioepis, Santen, Senju, Taiwan Liposome Company, Xbrane BioPharma Charles C. Wykoff, MD, PhD Speaker's Bureau: Regeneron

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Yaremi Koopot, and Alana Ochoa all have reported that they do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and iVista Medical Education, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Session Agenda – Sunday, December 6, 2020: 10:00 AM – 12:30 PM ET Welcome & Overview

10:00 AM Introduction to INNOVATE 2020 Session III Quan Dong Nguyen, MD, MSc

Section 1 – Diabetic Retinopathy: What Now, What Next?

10:05 AM Introduction to Section 1 Diana V. Do, MD

10:07 AM What Do I Do with Anti-VEGF Non-Responders? Jennifer Lim, MD

10:13 AM Burden of Treating Your Diabetic Retinopathy Patient... Why Bother or Why Not? Charles C. Wykoff, MD, PhD

10:19 AM Emerging Therapies for Diabetic Macular Edema Arshad Kahanani, MD, MA

10:25 AM Break

Panel Discussions (Attendees will have the option to choose which panel discussion to attend.)

10:27 AM Panel 1: Current Clinical Management and Unmet Needs Moderator: Diana V. Do, MD Panelists: Jennifer Lim, MD; Dante J. Pieracmi, MD; Charles C. Wykoff, MD, PhD

10:27 AM Panel 2: Clinical Trials and Emerging Therapies in DR and DME (Non-CME) Moderator: Quan Dong Nguyen, MD, MSc Panelists: Arshad Khanani, MD, MA; Derek Y. Kunimoto, MD, JD; Baruch D. Kuppermann, MD, PhD

10:57 AM Break

Section 2 – Molecular and Gene Therapy: New Frontiers in Retina

11:00 AM Introduction to Section 2 Vinit B. Mahajan, MD, PhD

11:01 AM Molecular Surgery: Combining Molecular Biology and Vitreoretinal Surgery for Innovation Vinit B. Mahajan, MD, PhD

11:07 AM Surgical Approaches to Viral Vector-Based Anti-VEGF Therapies Allen C. Ho, MD, FACS

11:13 AM In Office Gene Therapy and Next Gen Therapies David S. Boyer, MD

11:18 AM Retinal Gene Therapy in Pediatric Patients: Unique Challenges Audina Berrocal, MD

11:24 AM Break

Panel Discussions (Attendees will have the option to choose which panel discussion to attend.)

11:26 AM Panel 1: Vector-Based Therapy for Ocular Diseases: Pros and Cons Moderator: Quan Dong Nguyen, MD, MSc Panelists: Audina Berrocal, MD; David S. Boyer, MD; Allen C. Ho, MD, FACS; Mark Pennesi, MD, PhD

11:26 AM Panel 2: Unmet Needs and New Technologies in Gene Therapy (Non-CME) Moderator: Prithvi Mruthyunjaya, MD, MHS Panelists: Anirvan Ghosh, PhD; Robert MacLaren, MD, ChB DPhil, FRCOphth, FRCS FACS, FMedSci; Vinit B. Mahajan, MD, PhD; Camille Samuels, MBA

11:46 AM Break

Section 3 – The Future of Vitreoretinal Surgery

11:48 AM Introduction to Section 3 Prithvi Mruthyunjaya, MD, MHS

11:49 AM Intraoperative OCT Imaging Cynthia A. Toth, MD

11:55 AM Improving on Surgical Viewing Systems Anat Loewenstein, MD

12:01 PM Engineering Approach to Artificial Vision Ruwan A. Silva, MD, Mphil

12:07 PM Break

12:09 PM Innovating Next-Generation VR Surgical Instrumentation (Non-CME) Tamer Mahmoud, MD, PhD

12:15 PM Introduction to Capitalizing on Innovation (Non-CME) Stephen Smith, MD

Panel Discussions (Attendees will have the option to choose which panel discussion to attend.)

12:17 PM Panel 1: Future of VR Surgery Moderators: Prithvi Mruthyunjaya, MD, MHS and Justis P. Ehlers, MD Panelists: Anat Loewenstein, MD; Tamer Mahmoud, MD, PhD; Ruwan A. Silva, MD, MPhil; Cynthia A. Toth, MD

12:17 PM Panel 2: Capitalizing on Innovation Panel: The Retina Side Hustle (Non-CME) Moderator: Stephen Smith, MD Panelists: Eugene de Juan, MD; Anne E. Fung, MD; Linda A. Lam, MD, MBA; Nathan Steinle, MD

12:30 PM Closing Comments